Evidence-Based Management of Arrhythmogenic Right Ventricular Cardiomyopathy in Pregnancy

Authors

Jagjit Khosla
Reshma Golamari
Alice Cai
Jamal Benson
Wilbert S. Aronow, New York Medical CollegeFollow
Rahul Jain
Rohit Jain

Author Type(s)

Faculty

Journal Title

Future Cardiology

First Page

693

Last Page

703

Document Type

Article

Publication Date

7-2021

Department

Medicine

Abstract

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder resulting in fibrofatty replacement of the myocardium. Genetic mutations in genes encoding for desmosome proteins result in a ventricular myocardium prone to arrhythmias and heart failure. Although ARVC is known for a few decades, most of the outcomes in pregnancy are reported recently. Pregnancy leads to significant physiological changes with excess mechanical stress on the myocardium. All the retrospective studies suggest that pregnancy is well tolerated in these patients despite the high risk of arrhythmias and heart failure. Our review focuses on the most up-to-date evidence on the management of ARVC patients during the antepartum and postpartum period.

Recommended Citation

Khosla, J., Golamari, R., Cai, A., Benson, J., Aronow, W. S., Jain, R., & Jain, R. (2021). Evidence-Based Management of Arrhythmogenic Right Ventricular Cardiomyopathy in Pregnancy. Future Cardiology, 17 (4), 693-703. https://doi.org/10.2217/fca-2020-0127